Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation

• Published in: Frontiers in immunology 2020-03, Vol.11, p.407-407
• Main Authors: Ngamsri, Kristian-Christos, Jans, Christoph, Putri, Rizki A, Schindler, Katharina, Gamper-Tsigaras, Jutta, Eggstein, Claudia, Köhler, David, Konrad, Franziska M
• Format: Article
• Language: English
• Subjects: Acute Disease; adenosine receptor A2B; Animals; Benzylamines - pharmacology; Benzylamines - therapeutic use; Capillary Permeability; Chemokine CXCL12 - metabolism; Cyclams - pharmacology; Cyclams - therapeutic use; Disease Models, Animal; Humans; Immunology; Mice; Mice, Inbred C57BL; Mice, Knockout; neutrophil; Neutrophils - immunology; Peritonitis - drug therapy; PMN; Receptor, Adenosine A2B - genetics; Receptor, Adenosine A2B - metabolism; Receptors, CXCR - antagonists & inhibitors; Receptors, CXCR - metabolism; Receptors, CXCR4 - antagonists & inhibitors; Receptors, CXCR4 - metabolism; SDF-1; Sepsis - drug therapy; Signal Transduction; stromal cell-derived factor; tight junction proteins
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2020.00407

Our previous studies revealed a pivotal role of the chemokine stromal cell-derived factor (SDF)-1 and its receptors CXCR4 and CXCR7 on migratory behavior of polymorphonuclear granulocytes (PMNs) in pulmonary inflammation. Thereby, the SDF-1-CXCR4/CXCR7-axis was linked with adenosine signaling. However, the role of the SDF-1 receptors CXCR4 and CXCR7 in acute inflammatory peritonitis and peritonitis-related sepsis still remained unknown. The presented study provides new insight on the mechanism of a selective inhibition of CXCR4 (AMD3100) and CXCR7 (CCX771) in two models of peritonitis and peritonitis-related sepsis by injection of zymosan and fecal solution. We observed an increased expression of SDF-1, CXCR4, and CXCR7 in peritoneal tissue and various organs during acute inflammatory peritonitis. Selective inhibition of CXCR4 and CXCR7 reduced PMN accumulation in the peritoneal fluid and infiltration of neutrophils in lung and liver tissue in both models. Both inhibitors had no anti-inflammatory effects in A knockout animals (A -/-). AMD3100 and CCX771 treatment reduced capillary leakage and increased formation of tight junctions as a marker for microvascular permeability in wild type animals. In contrast, both inhibitors failed to improve capillary leakage in A -/- animals, highlighting the impact of the A -receptor in SDF-1 mediated signaling. After inflammation, the CXCR4 and CXCR7 antagonist induced an enhanced expression of the protective A adenosine receptor and an increased activation of cAMP (cyclic adenosine mono phosphate) response element-binding protein (CREB), as downstream signaling pathway of A . The CXCR4- and CXCR7-inhibitor reduced the release of cytokines in wild type animals via decreased intracellular phosphorylation of ERK and NFκB p65. , CXCR4 and CXCR7 antagonism diminished the chemokine release of human cells and increased cellular integrity by enhancing the expression of tight junctions. These protective effects were linked with functional A -receptor signaling, confirming our data. In conclusion, our study revealed new protective aspects of the pharmacological modulation of the SDF-1-CXCR4/CXCR7-axis during acute peritoneal inflammation in terms of the two hallmarks PMN migration and barrier integrity. Both anti-inflammatory effects were linked with functional adenosine A -receptor signaling.